The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of KRAS/NRAS, PI3CA, and BRAF mutations in the phase II KSCC0901 study of cetuximab plus S-1 as third-line treatment for metastatic colorectal cancer in Japanese patients.
Yasunori Emi
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Hiroshi Saeki
No relevant relationships to disclose
Hiroyuki Kitao
No relevant relationships to disclose
Hironori Samura
No relevant relationships to disclose
Takao Takahashi
No relevant relationships to disclose
Terumitsu Sawai
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose
Akihito Tsuji
No relevant relationships to disclose
Susumu Eguchi
No relevant relationships to disclose
Kazuhiro Yoshida
Research Funding - Taiho Pharmaceutical
Hideo Baba
Research Funding - Taiho Pharmaceutical
Yutaka Ogata
No relevant relationships to disclose
Shoji Natsugoe
Research Funding - Taiho Pharmaceutical
Mototugu Shimokawa
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Taiho Pharmaceutical